CrossrefInfokarte
Drugging the luminal axis end to end: A review of next-generation endocrine and targeted therapies in HR + /HER2- metastatic breast cancer
European Journal of Cancer · 2026-12 · 249 · 117794
DOI: 10.1016/j.ejca.2026.117794 ↗Abstract
Kein Abstract verfügbar.
EUVIMED